Tanvex BioPharma, Inc. (TPE:6541)
55.90
-0.20 (-0.36%)
Dec 3, 2025, 1:35 PM CST
Tanvex BioPharma Revenue
Tanvex BioPharma had revenue of 125.34M TWD in the quarter ending September 30, 2025, with 989.60% growth. This brings the company's revenue in the last twelve months to 224.83M, up 448.96% year-over-year. In the year 2024, Tanvex BioPharma had annual revenue of 34.68M, down -43.53%.
Revenue (ttm)
224.83M
Revenue Growth
+448.96%
P/S Ratio
66.08
Revenue / Employee
n/a
Employees
200
Market Cap
14.86B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 34.68M | -26.73M | -43.53% |
| Dec 31, 2023 | 61.41M | 39.01M | 174.11% |
| Dec 31, 2022 | 22.40M | 17.00M | 314.43% |
| Dec 31, 2021 | 5.41M | 5.11M | 1,702.00% |
| Dec 31, 2020 | 300.00K | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bora Pharmaceuticals Co., LTD. | 21.10B |
| Lotus Pharmaceutical | 18.66B |
| PharmaEssentia | 13.82B |
| Pegavision | 6.90B |
| Center Laboratories | 1.57B |
| Oneness Biotech | 117.33M |
| Polaris Group | 70.83M |
| Lumosa Therapeutics | 42.59M |